Tonsillar B Cells Do Not Express PSGL-1, but a Significant Fraction Displays the Cutaneous Lymphocyte Antigen and Exhibits Effective E- and P-Selectin Ligand Activity

2001 ◽  
Vol 126 (1) ◽  
pp. 78-90 ◽  
Author(s):  
Dieter Armerding ◽  
Robert C. Fuhlbrigge ◽  
J. David Kieffer ◽  
Thomas S. Kupper
Keyword(s):  
B Cells ◽  
Significant Fraction ◽  
Lymphocyte Antigen ◽  
Selectin Ligand ◽  
Cutaneous Lymphocyte Antigen ◽  
Ligand Activity

scholarly journals Cutaneous lymphocyte antigen expression on human effector B cells depends on the site and on the nature of antigen encounter

2003 ◽  
Vol 33 (12) ◽  
pp. 3275-3283 ◽  
Author(s):  
Anu Kantele ◽  
Erkki Savilahti ◽  
Heidi Tiimonen ◽  
Katja Iikkanen ◽  
Soile Autio ◽  
...  
Keyword(s):  
B Cells ◽  
Antigen Expression ◽  
Lymphocyte Antigen ◽  
Cutaneous Lymphocyte Antigen

Cutaneous Lymphocyte Antigen Is Expressed on Memory/Effector B Cells in the Peripheral Blood and Monocytoid B Cells in the Lymphoid Tissues

1999 ◽  
Vol 197 (1) ◽  
pp. 39-45 ◽  
Author(s):  
Tadashi Yoshino ◽  
Mitsuhiro Okano ◽  
Hong-Li Chen ◽  
Junjiro Tsuchiyama ◽  
Eisaku Kondo ◽  
...  
Keyword(s):  
B Cells ◽  
Peripheral Blood ◽  
Lymphoid Tissues ◽  
Lymphocyte Antigen ◽  
Cutaneous Lymphocyte Antigen

scholarly journals The Cutaneous Lymphocyte Antigen Is an Essential Component of the L-selectin Ligand Induced on Human Vascular Endothelial Cells

1999 ◽  
Vol 189 (2) ◽  
pp. 241-252 ◽  
Author(s):  
LiLi Tu ◽  
Martha D. Delahunty ◽  
Han Ding ◽  
Francis W. Luscinskas ◽  
Thomas F. Tedder
Keyword(s):  
Endothelial Cells ◽  
Vascular Endothelium ◽  
Vascular Endothelial Cell ◽  
Vascular Endothelial ◽  
Human Vascular Endothelial Cell ◽  
Lymphocyte Antigen ◽  
Selectin Ligands ◽  
Ligand Expression ◽  
Selectin Ligand ◽  
Cutaneous Lymphocyte Antigen

L-selectin mediates leukocyte rolling on vascular endothelium during inflammation. Although vascular endothelium can be activated with inflammatory cytokines to express functional L-selectin ligands, these ligands have not been well characterized. In this study, fucosyltransferase VII cDNA (Fuc-TVII) transfection of the EA.hy926 human vascular endothelial cell line (926-FtVII) induced functional L-selectin ligand expression and expression of sialyl Lewisx (sLex), as defined by HECA-452 (cutaneous lymphocyte antigen; CLA) and CSLEX-1 mAbs. Cytokine activation of human umbilical vein endothelial cells (HUVEC) also induced functional L-selectin ligand expression, with increased CLA expression and Fuc-TVII transcription. The majority of L-selectin–dependent lymphocyte attachment to activated HUVEC and 926-FtVII cells was blocked specifically by treating the endothelial cells with the HECA-452 mAb, but not the CSLEX-1 mAb. CLA-bearing ligands on vascular endothelium also required sulfation and appropriate molecular scaffolds for functional activity, but were distinct from the L-selectin ligands previously identified by the MECA-79 mAb. These findings demonstrate that the HECA-452– defined antigen, CLA, is an essential carbohydrate component of vascular L-selectin ligands.

Primary Cutaneous ALCL With Phosphorylated/Activated Cytoplasmic ALK and Novel Phenotype: EMA/MUC1+, Cutaneous Lymphocyte Antigen Negative

2008 ◽  
Vol 32 (9) ◽  
pp. 1421-1426 ◽  
Author(s):  
Marshall E. Kadin ◽  
Jack L. Pinkus ◽  
Geraldine S. Pinkus ◽  
Ivan H. Duran ◽  
Christine E. Fuller ◽  
...  
Keyword(s):  
Lymphocyte Antigen ◽  
Cutaneous Lymphocyte Antigen

Targeting the cutaneous lymphocyte antigen (CLA) in inflammatory and neoplastic skin conditions

2020 ◽  
Vol 20 (3) ◽  
pp. 275-282 ◽  
Author(s):  
Alvise Sernicola ◽  
Irene Russo ◽  
Micol Silic-Benussi ◽  
Vincenzo Ciminale ◽  
Mauro Alaibac
Keyword(s):  
Lymphocyte Antigen ◽  
Cutaneous Lymphocyte Antigen ◽  
Skin Conditions

Current targeted therapies in lymphomas

2019 ◽  
Vol 76 (22) ◽  
pp. 1825-1834
Author(s):  
Clement Chung
Keyword(s):  
T Cell ◽  
B Cells ◽  
Adverse Effects ◽  
Cell Surface ◽  
Supportive Care ◽  
B Cell ◽  
Targeted Therapies ◽  
B Cell Lymphoma ◽  
Lymphocyte Antigen ◽  
T Cell Lymphomas

Abstract Purpose This article summarizes current targeted therapies that have received regulatory approval for the treatment of B- and T-cell lymphomas. Summary Over the last 20 years, new drug therapies for lymphomas of B cells and T cells have expanded considerably. Targeted therapies for B-cell lymphomas include: (1) monoclonal antibodies directed at the CD20 lymphocyte antigen, examples of which are rituximab, ofatumumab, and obinutuzumab; (2) gene transfer therapy, an example of which is chimeric antigen receptor–modified T-cell (CAR-T) therapy directed at the CD19 antigen expressed on the cell surface of both immature and mature B cells; and (3) small-molecule inhibitors (ibrutinib, acalabrutinib, copanlisib, duvelisib, and idelalisib) that target the B-cell receptor signaling pathway. Of note, brentuximab vedotin is an antibody–drug conjugate that targets CD30, another lymphocyte antigen expressed on the cell surface of both Hodgkin lymphoma (a variant of B-cell lymphoma) and some T-cell lymphomas. Although aberrant epigenetic signaling pathways are present in both B- and T-cell lymphomas, epigenetic inhibitors (examples include belinostat, vorinostat, and romidepsin) are currently approved by the Food and Drug Administration for T-cell lymphomas only. In addition, therapies that target the tumor microenvironment have been developed. Examples include mogamulizumab, bortezomib, lenalidomide, nivolumab, and pembrolizumab. In summary, the efficacy of these agents has led to the development of supportive care to mitigate adverse effects, due to the presence of on- or off-target toxicities. Conclusion The therapeutic landscape of lymphomas has continued to evolve. In turn, the efficacy of these agents has led to the development of supportive care to mitigate adverse effects, due to the presence of on- or off-target toxicities. Further opportunities are warranted to identify patients who are most likely to achieve durable response and reduce the risk of disease progression. Ongoing trials with current and investigational agents may further elucidate their place in therapy and therapeutic benefits.

scholarly journals EBI2 Guides Serial Movements of Activated B Cells and Ligand Activity Is Detectable in Lymphoid and Nonlymphoid Tissues

2011 ◽  
Vol 187 (6) ◽  
pp. 3026-3032 ◽  
Author(s):  
Lisa M. Kelly ◽  
João P. Pereira ◽  
Tangsheng Yi ◽  
Ying Xu ◽  
Jason G. Cyster
Keyword(s):  
B Cells ◽  
Ligand Activity ◽  
Activated B Cells

IL-31 is associated with cutaneous lymphocyte antigen–positive skin homing T cells in patients with atopic dermatitis

2006 ◽  
Vol 117 (2) ◽  
pp. 418-425 ◽  
Author(s):  
Janine Bilsborough ◽  
Donald Y.M. Leung ◽  
Mark Maurer ◽  
Michael Howell ◽  
Mark Boguniewcz ◽  
...  
Keyword(s):  
T Cells ◽  
Atopic Dermatitis ◽  
Positive Skin ◽  
Lymphocyte Antigen ◽  
Skin Homing ◽  
Cutaneous Lymphocyte Antigen
Sign in / Sign up

Export Citation Format

Share Document